Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has shared an announcement.
CSL Limited has announced the issuance of 1,592,335 unquoted securities under an employee incentive scheme. These securities are subject to transfer restrictions and will not be quoted on the ASX until the restrictions are lifted. This move is part of CSL’s strategy to incentivize and retain talent, which is crucial for maintaining its competitive edge in the biotechnology sector.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on developing and delivering innovative medicines that save lives and improve the quality of life for people with rare and serious diseases. The company is a global leader in the production of plasma-derived therapies and influenza vaccines, with a strong emphasis on research and development to address unmet medical needs.
Average Trading Volume: 1,021,659
Technical Sentiment Signal: Sell
Current Market Cap: A$101.5B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.